MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy - Wikidata - awgldk - TriplyDB

MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy

MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy

http://www.wikidata.org/entity/Q33878029

about

Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers Development of a magnetic resonance imaging protocol to visualize encapsulated contrast agent markers in prostate brachytherapy recipients: initial patient experience Effect of pulse sequence parameter selection on signal strength in positive-contrast MRI markers for MRI-based prostate postimplant assessment.Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy.Image-guided prostate brachytherapy should be MRI-based.Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers.Reversible magnetogenic cobalt complexes

P2860

Q26738622-0E032A8A-D378-4DD4-9D19-AE1FAA4C88B3 Q28828463-843D73C1-B4C2-4FF0-84B2-CE5FD6AAA17D Q33708193-BAF4CE22-3901-470F-B7E1-593E7E8E2309 Q39073417-1C3743EB-D456-452D-A155-A6B25CE5ED84 Q54389424-E0F97752-865C-419A-8BDA-7CDD6B6FA62F Q55427963-8732EDEC-E9D8-492E-9512-227A949D93DF Q56434351-D2EC1DCF-AB5A-413E-8749-FB4B16F9FC2A

P2860

MRI characterization of cobalt dichloride-N-acetyl cysteine (C4) contrast agent marker for prostate brachytherapy

http://www.wikidata.org/entity/Q33878029

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

MRI characterization of cobalt ...... ker for prostate brachytherapy

@ast

MRI characterization of cobalt ...... ker for prostate brachytherapy

@en

type

label

MRI characterization of cobalt ...... ker for prostate brachytherapy

@ast

MRI characterization of cobalt ...... ker for prostate brachytherapy

@en

prefLabel

MRI characterization of cobalt ...... ker for prostate brachytherapy

@ast

MRI characterization of cobalt ...... ker for prostate brachytherapy

@en

P1433

Q33878029-65FCD743-E893-4015-87A9-18767094F1BB

P1476

Q33878029-2CDA42F6-19DB-4042-99A1-CE5E4A9C76F6

P2093

Q33878029-106CE52F-BC12-4D05-BBEB-218A3A51B93A

Q33878029-63BBC4C4-6D7D-4D65-8D89-148048625FB8

Q33878029-6708619E-B207-4960-936C-69991C6DBB03

Q33878029-977F0C10-ED63-4585-80F5-FC43A6FA6149

Q33878029-D44BCED9-07B5-4BDB-9A3E-87A21A1891BE

Q33878029-F1039C78-8FF4-4043-B92D-9F058010016B

Q33878029-F63A7E52-FFD0-450A-843E-4165FE269CEC

P2860

Q33878029-0995338F-A045-4569-B1C1-70B3203D8154

Q33878029-49226E3F-DDC4-4983-BCA3-8AC4DA7F107D

Q33878029-5CBC26E8-2F99-48D0-8762-6C012C9CD759

Q33878029-71B0188F-751F-4127-B4B4-0854D6E9235B

Q33878029-8716F9AA-04D3-4CBA-88E9-2264CDC936D8

Q33878029-92A1C025-1E5E-4AE1-9D6F-5C29F2182DE3

Q33878029-CE3751E8-ADBC-4BE1-B524-261B4DD70A30

Q33878029-ECE4C2AC-2E12-475A-AEB5-169FAA72CFBF

Q33878029-FFF2C6B1-FA2C-4527-8158-2B12F499B580

P304

Q33878029-174BF04B-406C-4D34-AA29-C019872A5CE3

P31

Q33878029-6C4E9FDB-1553-4EF5-853A-7A91039B123A

P356

Q33878029-E62A54DC-AB0A-456D-A1A9-1352ACE51557

P433

Q33878029-FABEAE43-D376-475B-9AD3-5F060CF982C2

P478

Q33878029-D33F917E-4151-437D-AB88-73071F68FFF1

P50

Q33878029-6B7655AA-68CD-4296-8205-FCB07D12CE91

P577

Q33878029-01E10681-4F9B-4E3C-A58C-0AF2FBE64CDD

P698

Q33878029-FC062A49-50E8-4A2A-8E0A-381EB8210610

P921

Q33878029-2c90baac-6293-4872-96d9-4f14a559af63

Q33878029-863995FA-EE82-4E92-98CC-317339F7E617

P932

Q33878029-A7570E6D-C121-4A2D-8492-C9C3C59FD993

P356

P1433

Physics in Medicine and Biology

P1476

MRI characterization of cobalt ...... ker for prostate brachytherapy

@en

P2093

Arvind Rao

http://www.w3.org/2001/XMLSchema#string

Geoffrey Ibbott

http://www.w3.org/2001/XMLSchema#string

Karen S Martirosyan

http://www.w3.org/2001/XMLSchema#string

Madhuri Sankaranarayanapillai

http://www.w3.org/2001/XMLSchema#string

R Jason Stafford

http://www.w3.org/2001/XMLSchema#string

Rajat J Kudchadker

http://www.w3.org/2001/XMLSchema#string

Steven J Frank

http://www.w3.org/2001/XMLSchema#string

P2860

ESUR prostate MR guidelines 2012

MRI contrast agents: basic chemistry and safety.

Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy.

T1/T2*-weighted MRI provides clinically relevant pseudo-CT density data for the pelvic bones in MRI-only based radiotherapy treatment planning.

A biodistribution and toxicity study of cobalt dichloride-N-acetyl cysteine in an implantable MRI marker for prostate cancer treatment.

A novel MRI marker for prostate brachytherapy.

MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results.

1H T1 and T2 measurements of the MR imaging contrast agents Gd-DTPA and Gd-DTPA BMA at 1.5T.

Positive contrast MRI of prostate brachytherapy seeds based on resonant frequency offset mapping

P304

2505-2516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1088/0031-9155/59/10/2505

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24778352

http://www.w3.org/2001/XMLSchema#string

P921

Béésh Łibáhí

P932

4090919

http://www.w3.org/2001/XMLSchema#string